BRPI0915119B8 - uso de iota carragenano - Google Patents

uso de iota carragenano

Info

Publication number
BRPI0915119B8
BRPI0915119B8 BRPI0915119A BRPI0915119A BRPI0915119B8 BR PI0915119 B8 BRPI0915119 B8 BR PI0915119B8 BR PI0915119 A BRPI0915119 A BR PI0915119A BR PI0915119 A BRPI0915119 A BR PI0915119A BR PI0915119 B8 BRPI0915119 B8 BR PI0915119B8
Authority
BR
Brazil
Prior art keywords
carrageenan
iota
therapeutic agents
relates
treatment
Prior art date
Application number
BRPI0915119A
Other languages
English (en)
Inventor
Grassauer Andreas
Prieschl-Grassauer Eva
Original Assignee
Marinomed Biotechnologie Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marinomed Biotechnologie Gmbh filed Critical Marinomed Biotechnologie Gmbh
Publication of BRPI0915119A2 publication Critical patent/BRPI0915119A2/pt
Publication of BRPI0915119B1 publication Critical patent/BRPI0915119B1/pt
Publication of BRPI0915119B8 publication Critical patent/BRPI0915119B8/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/731Carrageenans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/12Mucolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

uso de iota carragenano a presente invenção refere-se a composições farmacêuticas com base em carragenano como um ingrediente ativo, para uso como um medicamento no tratamento profilático ou terapêutico de condições ou de doenças alérgicas, com a condição de que o carragenano compreende iota e/ou kappa carragenano e é substancialmente livre de lambda carragenano. tipicamente, a invenção refere-se a formulações líquidas, géis e a composições em pó seco que compreendem iota e/ou kappa carragenano e, opcionalmente, um ou mais agentes terapêuticos para administração ao trato respiratório, ao trato gastrintestinal ou aos olhos. foi descoberto que as composições da invenção são eficazes na prevenção e no tratamento de alergias do tipo i e adicionalmente podem exercer uma função adjuvante por administração combinada às mucosas com agentes terapêuticos sem ser de carragenano.
BRPI0915119A 2008-07-01 2009-06-30 uso de iota carragenano BRPI0915119B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12950708P 2008-07-01 2008-07-01
US61/129507 2008-07-01
PCT/EP2009/004696 WO2010000437A1 (en) 2008-07-01 2009-06-30 Antiallergic marine biopolymers

Publications (3)

Publication Number Publication Date
BRPI0915119A2 BRPI0915119A2 (pt) 2016-02-10
BRPI0915119B1 BRPI0915119B1 (pt) 2021-02-17
BRPI0915119B8 true BRPI0915119B8 (pt) 2021-05-25

Family

ID=41127843

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0915119A BRPI0915119B8 (pt) 2008-07-01 2009-06-30 uso de iota carragenano

Country Status (18)

Country Link
US (2) US20110091583A1 (pt)
EP (1) EP2303287B1 (pt)
JP (1) JP5687619B2 (pt)
CN (1) CN102065869B (pt)
AU (1) AU2009266076B2 (pt)
BR (1) BRPI0915119B8 (pt)
CA (1) CA2726221C (pt)
DK (1) DK2303287T3 (pt)
EA (1) EA020222B1 (pt)
ES (1) ES2445870T3 (pt)
HR (1) HRP20140164T1 (pt)
MX (1) MX2010013567A (pt)
NZ (1) NZ589293A (pt)
PL (1) PL2303287T3 (pt)
PT (1) PT2303287E (pt)
SG (1) SG191697A1 (pt)
SI (1) SI2303287T1 (pt)
WO (1) WO2010000437A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013006795A2 (en) 2011-07-07 2013-01-10 Humanitas International Foundation Antiviral compositions and methods of their use
DE202013000445U1 (de) * 2012-10-04 2013-10-07 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Zusammensetzung, insbesondere pharmazeutische Zusammensetzung, insbesondere zur Verabreichung bei Heiserkeit
AU2014229072B2 (en) * 2013-03-15 2019-01-24 Hyprotek, Inc. Multi-chamber injection device
CN103301065A (zh) * 2013-06-27 2013-09-18 辽宁亿灵科创生物医药科技有限公司 一种海藻提取物的鼻喷剂及其制备方法
RS59437B1 (sr) * 2013-12-03 2019-11-29 Gerolymatos Int S A Jonske vodene kompozicije
HUE044329T2 (hu) * 2014-01-22 2019-10-28 Visufarma B V Iota-karragént tartalmazó készítmény vírusos kötõhártya-gyulladás ellen
CN104147603A (zh) * 2014-08-04 2014-11-19 辽宁亿灵科创生物医药科技有限公司 一种新型海藻提取物组合物在预防病毒性感冒中的应用
AR108280A1 (es) * 2016-05-05 2018-08-08 Acraf Composición oftálmica que comprende una combinación sinérgica de glucógeno y ácido hialurónico o sal del mismo
CN108498473A (zh) * 2018-06-28 2018-09-07 哈尔滨珍宝制药有限公司 一种包含孟鲁司特钠的药物组合物及其制备方法和用途
CN108498474A (zh) * 2018-06-28 2018-09-07 哈尔滨珍宝制药有限公司 一种包含盐酸曲美他嗪的药物组合物及其制备方法和用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6244265B1 (en) * 1997-01-29 2001-06-12 Peter J. Cronk Adhesively applied external nasal strips and dilators containing medications and fragrances
US6447816B1 (en) * 2000-04-03 2002-09-10 Inhalation, Inc. Methods and apparatus to prevent colds, flus, and infections of the human respiratory system
FR2808687B1 (fr) * 2000-04-27 2003-12-05 Goemar Lab Sa Medicament contenant des substances polysaccharidiques pour l'activation de l'apoptose
WO2002040056A2 (en) * 2000-11-06 2002-05-23 Alcon, Inc Carrageenan viscoelastics for ocular surgery
JP2003081841A (ja) * 2001-06-26 2003-03-19 Kikkoman Corp 抗アレルギー体質強化剤
US20060078504A1 (en) * 2003-02-26 2006-04-13 Akira Yamamoto Sustanined-release pharmaceutical composition for lung administration
EP1884245A1 (en) * 2006-08-04 2008-02-06 Marinomed Biotechnologie GmbH Use of Escin
US20080131454A1 (en) * 2006-12-05 2008-06-05 Marinomed Biotechnologie Gmbh Methods and Compositions for the Treatment of Rhinovirus Infections with Carrageenan
ATE462438T1 (de) * 2006-12-05 2010-04-15 Marinomed Biotechnologie Gmbh Verwendung von carrageenan zur behandlung von rhinovirus-infektionen
EP1930015A1 (en) * 2006-12-05 2008-06-11 Marinomed Biotechnologie GmbH Use of carrageenan for treating rhinovirus infections
BRPI0815748B8 (pt) * 2007-08-24 2021-05-25 Marinomed Biotechnologie Gmbh uso de iota-carragenina em uma quantidade antiviral eficaz

Also Published As

Publication number Publication date
CN102065869A (zh) 2011-05-18
MX2010013567A (es) 2011-01-21
EP2303287A1 (en) 2011-04-06
SG191697A1 (en) 2013-07-31
WO2010000437A1 (en) 2010-01-07
EP2303287B1 (en) 2013-12-11
JP2012531382A (ja) 2012-12-10
AU2009266076A1 (en) 2010-01-07
PL2303287T3 (pl) 2014-05-30
EA201170117A1 (ru) 2011-06-30
CA2726221A1 (en) 2010-01-07
BRPI0915119B1 (pt) 2021-02-17
US20110091583A1 (en) 2011-04-21
CN102065869B (zh) 2014-10-08
CA2726221C (en) 2017-03-28
NZ589293A (en) 2012-09-28
DK2303287T3 (en) 2014-02-17
PT2303287E (pt) 2014-02-27
EA020222B1 (ru) 2014-09-30
JP5687619B2 (ja) 2015-03-18
AU2009266076B2 (en) 2015-05-21
BRPI0915119A2 (pt) 2016-02-10
US20120058206A1 (en) 2012-03-08
HRP20140164T1 (hr) 2014-04-11
ES2445870T3 (es) 2014-03-05
SI2303287T1 (sl) 2014-04-30

Similar Documents

Publication Publication Date Title
BRPI0915119B8 (pt) uso de iota carragenano
BR112013022495A2 (pt) formulação farmacêutica aquosa de tapentadol para administração oral
CY1118813T1 (el) Φαρμακευτικες συνθεσεις συν-κρυσταλλων τραμαδολης και κοξιμπων
BR112015007814A2 (pt) diagnóstico, prevenção e tratamento de doenças da articulação
BR112016001446A8 (pt) composições terapêuticas, produto de combinação, uso in vitro de flecainida e flecainida
BR112012026596A2 (pt) método para preparar composições farmacêuticas pretendidas para administração oral compreendendo um ou mais ingredientes ativos e as composições que compreendem as mesmas
BR112015023922A2 (pt) composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes
BR112014008789A2 (pt) prevenção e tratamento de condições oculares
UA109991C2 (xx) Карбаматні сполуки, їх отримання і застосування
BR112015012197A8 (pt) usos de inibidores de cdk mtor, e combinação farmacêutica compreendendo os mesmos
CL2012001836A1 (es) Compuestos de pirazol, antagonista de crth2; composicion farmacéutica; uso en el tratamiento de trastornos inflamatorios, infecciosos, inmunoreguladores, enfermedades respiratorias, gastrointestinales o dolencias, entre otros.
BR112013026698A2 (pt) formulações do tipo tópica compreendendo depsipeptídeo cíclico
BR112012005044B8 (pt) composição farmacêutica que compreende uma combinação de (rac)-tramadol·hcl e celecoxib
BRPI0806392A8 (pt) uso de aclidínio, aclidínio, método de tratamento ou prevenção e composição farmacêutica
BR112015011430A2 (pt) composição para liberação imediata e prolongada
BR112015014174A2 (pt) composição de vacina para indivíduos virgens
BR112012012862A2 (pt) composição farmacêutica compreendendo oligopeptídeos
CO7101247A2 (es) Formulaciones de ácido poliinosínico-policitidílico (poli(i:c)) para el tratamiento de infecciones de las vías respiratorias altas
BR112015027017A2 (pt) composições farmacêuticas inaláveis e dispositivos inaladores que contêm as mesmas
BR112017009510A2 (pt) composições compreendendo ciclosporina
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
BR112014016472A8 (pt) formulação farmacêutica estável para administração oral que compreende levocetirizina ou um sal farmaceuticamente aceitável da mesma e montelukast ou um sal farmaceuticamente aceitável do mesmo
BR112015005942A2 (pt) extratos de cynara scolymus, coffea spp. e olea europaea para tratamento de síndrome metabólica
BR112013004562A2 (pt) 2-óxi-quinolina-3-carboxamidas substituídas como moduladores kcnq2/3
TR201004464A2 (tr) Kemik erimesi için formülasyon.

Legal Events

Date Code Title Description
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 17/02/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/06/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF